Skip to main content
TipRanks
Go Ultimate75% OFF

Artra Group Corporation (6029) AI Stock Analysis

0 Followers
JP:6029

Artra Group Corporation

(TSE/TYO:6029)

Select Model
Rating:69Neutral
Price Target:JPY 195.00▲(11.43% Upside)
Action:reiterated
Date:11/05/26

The company's strong financial turnaround, marked by improved profitability, cash flow, and a healthy balance sheet, is the most significant positive factor. However, the score is constrained by a persistent decline in revenue and weak technical momentum, with the stock trading below key short-term averages. The moderate valuation partially offsets these concerns, but the lack of a dividend and clear growth catalysts limits upside potential.

Positive Factors
Improved ProfitabilityThe return to profitability and stronger margins improve the company’s ability to fund operations and withstand normal business pressure. A healthy gross margin also provides a foundation for rebuilding earnings, although sustaining these gains will depend on reversing the weak revenue trend.
Negative Factors
Revenue ContractionSeveral years of shrinking revenue indicate that the company has not yet demonstrated durable top-line expansion. Persistent contraction can limit operating leverage, constrain reinvestment and make the recent profitability recovery harder to sustain if margin gains cannot offset the smaller revenue base.

Artra Group Corporation (6029) vs. iShares MSCI Japan ETF (EWJ)

-20%-10%0%10%20%30%40%50%JP:6029+10.06%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 1.88B
Dividend Yield
―
Average Volume (3M)
103.06K
Price to Earnings (P/E)
9.1
Beta (1Y)
1.17
Revenue Growth
-11.43%
EPS Growth
-11.24%
Country
Japan
Employees
131
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Artra Group Corporation Business Overview & Revenue Model

Company Description

Artra Group Corporation delivers diverse support services to acupuncture and osteopathic clinics across Japan. Its offerings encompass billing solutions and HONEY-STYLE, a specialized platform facilitating word-of-mouth marketing and reservation mana...

Artra Group Corporation Financial Statement Overview

Summary

Financial health is solid, driven by strong margin expansion, positive net income, and a significantly deleveraged balance sheet. Robust free cash flow generation supports stability. The primary offset is a persistent multi-year revenue decline, which tempers the overall score.

Income Statement

70Positive

Balance Sheet

85Very Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.66B3.93B4.23B4.50B4.67B3.16B
Gross Profit1.28B1.35B1.33B1.46B1.57B876.25M
EBITDA295.24M360.55M146.84M228.12M190.55M-163.55M
Net Income96.77M258.29M-36.74M53.00M2.10M-351.12M
Balance Sheet
Total Assets3.40B4.13B4.11B4.57B4.65B5.60B
Cash, Cash Equivalents and Short-Term Investments1.18B1.13B1.05B1.14B1.23B1.84B
Total Debt742.97M1.05B1.29B1.54B1.91B2.44B
Total Liabilities1.74B2.43B2.68B3.13B3.35B4.16B
Stockholders Equity1.66B1.70B1.44B1.45B1.31B1.44B
Cash Flow
Free Cash Flow0246.64M122.36M142.00M-288.93M-264.76M
Operating Cash Flow0287.21M200.85M217.00M-132.55M-208.56M
Investing Cash Flow024.68M-31.16M-11.00M-154.17M-563.84M
Financing Cash Flow0-233.24M-259.74M-300.00M-314.62M895.50M

Artra Group Corporation Technical Analysis

Technical Analysis SentimentNegative
Last Price175.00

Price Trends

50DMA185.56Negative
100DMA188.65Negative
200DMA179.51Negative

Market Momentum

MACD-3.42Positive
RSI46.64Neutral
STOCH61.32Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6029, the sentiment is Negative. The current price of 175.00 is below the 20-day moving average (MA) of 181.10, below the 50-day MA of 185.56, and below the 200-day MA of 179.51, indicating a bearish trend. The MACD of -3.42 indicates Positive momentum. The RSI at 46.64 is Neutral, neither overbought nor oversold. The STOCH value of 61.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6029.

Artra Group Corporation Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:6029 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:9220JP:922079OutperformJPY 3.08B6.39―3.40%5.71%10.34%
JP:9214JP:921470OutperformJPY 1.91B13.21――27.36%22.17%
JP:6029JP:602969NeutralJPY 1.90B9.08――-11.43%-11.24%
JP:2373JP:237357NeutralJPY 5.21B18.02―4.46%4.76%-52.55%
JP:2425JP:242555NeutralJPY 2.50B28.45―3.34%-3.64%-66.52%
JP:7362JP:736252NeutralJPY 1.31B8.14――20.92%135.80%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%20%40%JP:6029JP:2373JP:2425JP:7362JP:9214JP:9220Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:6029 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:6029Artra Group Corporation175.0014.008.70%
JP:2373Care Twentyone Corporation381.00-47.26-11.04%
JP:2425Care Service Co., Ltd.659.00-103.11-13.53%
JP:7362Terminalcare Support Institute, Inc.856.0035.044.27%
JP:9214Recovery International Co.,Ltd.1350.00-70.00-4.93%
JP:9220FB CARE SERVICE CO.,LTD.1265.0079.626.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026